News & Articles 09/11/2023 Our Network AstraZeneca licenses novel agent for the treatment of cardiometabolic conditions and obesity Global rights to Eccogene’s next-generation oral glucagon-like peptide 1 receptor agonist, ECC5004 as monotherapy and combination therapies.
News & Articles 17/06/2023 Our Network Real-world evidence study shows the significant impact of hyperkalaemia on cardiorenal patient outcomes AstraZeneca’s real-world evidence (RWE) ZORA study shows the negative consequences of reducing or discontinuing life-saving renin-angiotensin-aldosterone system inhibitor (RAASi) medication in patients experiencing hyperkalaemia (HK).
